Worried about your State Pension income? Here are 2 FTSE 100 dividend stocks I’d buy today

These two FTSE 100 (INDEXFTSE:UKX) stocks could deliver improving income returns in my opinion.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With the State Pension amounting to just £8,767 per year, many retirees are likely to need a second income in older age.

Since the FTSE 100 appears to offer good value for money at the present time, with it having a dividend yield of around 4.5%, there are a number of opportunities to generate a growing passive income across the large-cap share universe.

With that in mind, here are two FTSE 100 stocks that could offer an improving income outlook, as well as relatively stable financial performance over the long term.

AstraZeneca

It’s been a difficult journey for pharmaceutical company AstraZeneca (LSE: AZN) over the last decade. It has seen its profitability fall heavily due to the loss of patents on key drugs, with this leading to a lack of dividend growth in recent years.

Now though, the company appears to be in a relatively strong position. It has invested heavily in its pipeline under a strategy that has sought to focus on core growth areas. This strategy is now expected to bear fruit, with the business forecast to post a rise in net profit of around 12% in the current year.

This could stimulate AstraZeneca’s dividend growth prospects, and lead to an improving income outlook for its investors. It now has a dividend yield of just 3.4%, but its potential to increase dividends at a pace that exceeds inflation could lead to a robust outlook from an income perspective.

Alongside this, the company’s defensive appeal could help it to outperform the wider FTSE 100 at a time when the prospects for the global economy remain highly uncertain.

Unilever

Unilever’s (LSE: ULVR) recent updates have shown that its current growth strategy is paying off. It has focused investment on fast-growing markets across the emerging world, with them now making up the lion’s share of its revenue. They are also the main catalyst behind the company’s growth rate, and are likely to remain so over the medium term as wages in countries such as China move higher at a rapid rate.

Like AstraZeneca, Unilever’s dividend yield is below that of the wider FTSE 100 at the present time. The consumer goods company is set to record an income return of just 2.9% in the current year. However, with its bottom line forecast to produce a gain of 10% this year and its dividend payments being covered 1.6 times by profit, the scope for a rapidly-rising dividend seems to be high.

Although Unilever may lack the defensive appeal of some of its FTSE 100 peers, its potential to enjoy above-average growth over the long run seems to be high. It has a wide range of popular brands in a number of different markets. This provides it with a wide economic moat which, alongside its growth potential, makes it an enticing income opportunity for the long term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca and Unilever. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

5 investment trusts to consider for a new 2025 ISA

The biggest challenge when starting an ISA is choosing which stocks to buy. Investment trusts can make it a whole…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Have I left it too late to buy Nvidia shares?

When the whole world was racing to buy Nvidia shares, Harvey Jones decided they were overhyped. Does the recent dip…

Read more »

Dividend Shares

I asked ChatGPT to pick me the best passive income stock. Here’s the result!

Jon Smith tries to make friends with ChatGPT and critiques the best passive income pick the AI tool suggested for…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Hargreaves Lansdown’s clients are buying loads of this US growth stock. Should I?

Our writer's noticed that during the week after Christmas, many investors bought this US growth stock. He asks whether he…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Greggs shares plunge 11% despite growing sales. Is this my chance to buy?

As the company’s Q4 trading update reveals 8% revenue growth, Greggs shares are falling sharply. Should Stephen Wright be rushing…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

Will ‘biggest ever Christmas’ help keep the Tesco share price climbing in 2025?

The Tesco share price had a great year in 2024. And if 2025 trading continues in the same way, we…

Read more »

Investing Articles

This dirt cheap UK income stock yields 8.7% and is forecast to rise 45% this year!

After a disappointing year Harvey Jones thinks this FTSE 100 income stock is now one worth considering for investors seeking…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

With much to be cheerful about, why is this FTSE 250 boss unhappy?

JD Wetherspoon, the FTSE 250 pub chain, is a British success story. But the government’s budget has failed to lift…

Read more »